Skip to main content

Targeting epigenetic REPROGRamming of innate immune cells in Atherosclerosis Management and other chronic inflammatory diseases

Objective

Up to 70% of cardiovascular events are not prevented by current therapeutic regimens. In search for additional, innovative strategies, immune cells have been recognized as key players contributing to atherosclerotic plaque progression and destabilization. Particularly the role of innate immune cells is of major interest, following the recent paradigm shift that innate immunity, considered to be incapable of learning ability, does exhibit a memory feature transduced via epigenetic modulation. Compelling evidence shows that atherosclerotic factors promote immune cell migration by pre-activation of innate immune cells. In this project called REPROGRAM, we aim to prove that innate immune cell activation via epigenetic reprogramming perpetuates the upheld systemic inflammatory state in cardiovascular disease which is common in other chronic inflammatory diseases. This opens a new therapeutic area in which epigenetic modulation of innate immune cells effectively decreases systemic inflammation impacting on chronic inflammation as well as the development of co-morbidities. The integrated use of in vitro, ex vivo and in vivo studies, including cells, mice and patients, allows translation from in vitro mechanisms to diseases (molecule-to-man) and extrapolation to cohorts (man-to-mass), enabling us to demonstrate relevance and therapeutic potential of targeting trained immunity in cardiovascular and chronic inflammatory diseases. Enforced by the promising data in oncology, the future prospects for epigenetic interventions in cardiovascular and chronic inflammatory diseases are eminent, attested by the large residual cardiovascular disease burden and the huge societal impact of other chronic inflammatory diseases. The REPROGRAM consortium consisting of key opinion leaders in the field of cardiovascular (systems) biology, immunology, epigenetic therapies and rheumatoid arthritis, with a large intersectoral network, guarantees rapid translation of early mechanistic discoveries

Call for proposal

H2020-PHC-2015-two-stage
See other projects for this call

Funding Scheme

RIA - Research and Innovation action

Coordinator

ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM
Address
Meibergdreef 15
1105AZ Amsterdam
Netherlands
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 1 112 625

Participants (10)

STICHTING KATHOLIEKE UNIVERSITEIT
Netherlands
EU contribution
€ 973 500
Address
Geert Grooteplein Noord 9
6525 EZ Nijmegen
Activity type
Higher or Secondary Education Establishments
LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN
Germany
EU contribution
€ 925 000
Address
Geschwister Scholl Platz 1
80539 Muenchen
Activity type
Higher or Secondary Education Establishments
REGION HOVEDSTADEN
Denmark
EU contribution
€ 255 000
Address
Kongens Vaenge 2
3400 Hillerod
Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
UNIVERSITATEA DE MEDICINA SI FARMACIE IULIU HATIEGANU CLUJ-NAPOCA
Romania
EU contribution
€ 232 500
Address
Victor Babes Street 8
400012 Cluj-napoca
Activity type
Higher or Secondary Education Establishments
UNIVERSITA DEGLI STUDI DI MILANO
Italy
EU contribution
€ 587 375
Address
Via Festa Del Perdono 7
20122 Milano
Activity type
Higher or Secondary Education Establishments
UNIVERSITAT ZURICH
Switzerland
EU contribution
€ 0
Address
Ramistrasse 71
8006 Zurich
Activity type
Higher or Secondary Education Establishments
THE GENERAL HOSPITAL CORPORATION
United States
EU contribution
€ 600 000
Address
Fruit Street 55
02114 Boston Ma
Activity type
Other
SENSILAB POLSKA SP ZOO - SKA
Poland
EU contribution
€ 117 500
Address
Ul Gen Mariana Langiewicza 58
95 050 Konstantynow Lodzki
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
INSTITUT DE RECHERCHES INTERNATIONALES SERVIER
France
EU contribution
€ 225 000
Address
Rue Carnot 50
92284 Suresnes
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
DESCIN BV
Netherlands
EU contribution
€ 221 500
Address
Conicksmeer 2
3645WG Vinkeveen
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)